Immunic reports new vidofludimus calcium data at MSToronto2026
Immunic presented four posters on vidofludimus calcium at MSToronto2026 on October 21, 2026. In the Phase 2 CALLIPER extension, 6.5% of patients had stopped treatment through January 27, 2026, while safety remained consistent with the blinded period. Exploratory analyses linked a 0.65-match reduction in EBV-specific T-cell signatures with cognitive improvement, and the company plans a Phase 3 progressive-MS program later this year.
Why it matters
The findings add clinical, biomarker and preclinical support for Immunic's development program, although several results are exploratory or preclinical. The company expects to begin a Phase 3 progressive-MS program later this year and receive top-line ENSURE results by year-end 2026.
Key facts
- 1The Phase 2 CALLIPER open-label extension recorded a 6.5% treatment discontinuation rate through January 27, 2026. prnewswire.com
- 2The extension's safety and tolerability findings appeared consistent with those from the double-blind period. prnewswire.com
- 3An exploratory analysis found a reduction of -0.65 EBV-specific T-cell receptor beta-chain matches versus placebo, with p=0.0004. prnewswire.com
- 4Immunic presented the data in four posters at the MSToronto2026 meeting, held October 21-23, 2026, in Toronto. prnewswire.com
- 5The company expects to start a Phase 3 program in progressive multiple sclerosis later this year. prnewswire.com
Open questions
- Material 2 additionally reports that the CALLIPER trial randomized 467 patients, that its primary endpoint was not met, and that 44.4% of open-label-extension participants experienced at least one treatment-emergent adverse event; these details are not included in the primary release.
- Material 2 reports additional post-hoc effect estimates of 2.47 times and 1.5 times, but those estimates are not reported in the other materials.
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.